Treating inflammation and inflammatory pain in mucosa using mucosal prolonged release bioadhesive therapeutic carriers
The present invention concerns a pharmaceutical composition comprising an alpha- 2 adrenergic receptor agonist for preventing or treating inflammatory pain and diseases in mucosa of oral cavity, pharynx and larynx. In another aspect the present invention provides mucosal bioadhesive slow release carriers for the extended and controlled release of alpha- 2 adrenergic receptor agonists that can be used on mucosal surfaces for preventing or treating inflammatory pain and diseases in mucosa of oral cavity.
1. A method of treating oral mucositis in a chemotherapy or radiation therapy cancer patient comprising administering to the oral cavity of the patient prior to the onset of oral mucositis a pharmaceutical composition comprising an effective amount of clonidine or a pharmaceutically acceptable salt thereof.
2. The method of claim 1 , wherein the oral mucositis is due to chemotherapy or radiation therapy.
3. The method of claim 1 , wherein the pharmaceutical composition is in the form of a mucoadhesive tablet and comprises a mucosal bioadhesive slow release carrier, which comprises:
at least one diluent;
at least one bioadhesive agent; and
at least one sustained release agent that provides sustained release of the clonidine or pharmaceutically acceptable salt thereof;
wherein the clonidine or pharmaceutically acceptable salt thereof is present in the composition in an amount from 0.05 to 0.4 mg.
4. The method of claim 3 , wherein the mucosal bioadhesive slow release carrier comprises:
0.001 to 10% by weight of the clonidine or pharmaceutically acceptable salt thereof;
1 to 75% by weight of the at least one diluent;
5 to 80% by weight of the at least one bioadhesive agent; and
5 to 80% by weight of the at least one sustained release agent.
5. The method of claim 3 , wherein the clonidine or pharmaceutically acceptable salt thereof comprises 0.05 mg or 0.1 mg base equivalents of clonidine hydrochloride.
6. The method of claim 1 , wherein the pharmaceutical composition is administered prior to the patient starting chemotherapy or radiation therapy.
7. The method of claim 1 , wherein the method reduces the severity of the oral mucositis.
8. The method of claim 1 , wherein the patient has cancer of the head and neck.
9. The method of claim 8 , wherein the clonidine or pharmaceutically acceptable salt thereof is present in the composition in an amount from 0.05 to 0.4 mg.
10. The method of claim 8 , wherein the clonidine or pharmaceutically acceptable salt thereof comprises 0.05 mg or 0.1 mg base equivalents of clonidine hydrochloride.
11. The method of claim 6 , wherein the clonidine or pharmaceutically acceptable salt thereof is present in the composition in an amount from 0.05 to 0.4 mg.
12. The method of claim 6 , wherein the clonidine or pharmaceutically acceptable salt thereof comprises 0.05 mg or 0.1 mg base equivalents of clonidine hydrochloride.
13. The method of claim 6 , wherein the pharmaceutical composition is administered one day prior to the patient starting radiation therapy.
14. The method of claim 1 , wherein the clonidine or pharmaceutically acceptable salt thereof is present in the composition in an amount from 0.05 to 0.4 mg.
15. The method of claim 1 , wherein the method reduces the duration of the oral mucositis.
16. The method of claim 1 , wherein the pharmaceutical composition is administered once daily.
17. The method of claim 1 , wherein the pharmaceutical composition is administered during ongoing chemotherapy or radiation therapy.
18. The method of claim 1 , wherein the administration continues once the patient has developed oral mucositis.
19. A method of treating oral mucositis in a chemotherapy or radiation therapy cancer patient comprising administering once daily to the oral cavity of the patient prior to the onset of oral mucositis a pharmaceutical composition comprising an effective amount of clonidine or a pharmaceutically acceptable salt thereof, wherein
the pharmaceutical composition comprises a mucosal bioadhesive slow release carrier that provides for sustained release of the clonidine or pharmaceutically acceptable salt thereof; and
the clonidine or pharmaceutically acceptable salt thereof is present in the composition in an amount from 0.05 to 0.4 mg.
20. The method of claim 19 , wherein the clonidine or pharmaceutically acceptable salt thereof comprises 0.05 mg or 0.1 mg base equivalents of clonidine hydrochloride.
21. The method of claim 19 , wherein the pharmaceutical composition is in the form of a mucoadhesive tablet.
22. The method of claim 19 , wherein the patient has cancer of the head and neck.
23. The method of claim 19 , wherein the method reduces the severity of the oral mucositis.
24. The method of claim 19 , wherein the method reduces the duration of the oral mucositis.
25. The method of claim 19 , wherein the administration continues once the patient has developed oral mucositis.
26. The method of claim 19 , wherein the pharmaceutical composition is administered during ongoing chemotherapy or radiation therapy.
27. The method of claim 19 , wherein the pharmaceutical composition is administered prior to the patient starting chemotherapy or radiation therapy.
28. The method of claim 1 , wherein the clonidine or pharmaceutically acceptable salt thereof is the sole active ingredient in the pharmaceutical composition.
29. The method of claim 1 , wherein the clonidine or pharmaceutically acceptable salt thereof comprises 0.05 mg or 0.1 mg base equivalents of clonidine hydrochloride.
30. A method of treating oral mucositis in a chemotherapy or radiation therapy cancer patient comprising:
administering to the oral cavity of the patient prior to the onset of oral mucositis a pharmaceutical composition comprising an effective amount of clonidine or a pharmaceutically acceptable salt thereof; and
administering the composition during ongoing chemotherapy or radiation therapy;
wherein the clonidine or pharmaceutically acceptable salt thereof is present in the composition in an amount from 0.05 to 0.4 mg.